iCardiac Launches Wide-Scope Safety Study
The late phase respiratory and cardiac safety study will involve 14,000 patients across 750 sites, the company's largest such trial in its history.
iCardiac, a core laboratory for cardiac safety and respiratory services, has begun enrolling patients in the company's largest-ever late phase respiratory and cardiac safety study. The three-year trial will be conducted at sites in 28 countries and will include about 340,000 pulmonary function tests and 90,000 ECG reviews, according to iCardiac.
In July 2015, the company acquired the clinical trials division of nSpire Health (read background on the deal here).
Read the full release.
Truqap Combination Shines in Phase III Trial for Prostate Cancer
November 26th 2024Data from the CAPItello-281 trial show Truqap alongside abiraterone and androgen deprivation therapy achieved a statistically significant and clinically meaningful improvement in radiographic progression-free survival.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
